A separate analysis of the real-world trial found that those who switched from daily antiretroviral treatment to Cabenuva had fewer concerns about treatment.

The World Health Organization has suggested global release of lenacapavir, a twice-yearly injectable medication, as a powerful HIV infection-fighting medication. The historic suggestion was made ...

Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

IAS – the International AIDS Society – welcomes the bipartisan move in the US Senate to protect the President’s Emergency Plan for AIDS Relief (PEPFAR) from proposed USD 400 million cuts in President ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

In Summary Kenya is selected as one of the nine early adopters to implementation of HIV prevention Drug Lenacapavir. The ...

A new rapid test panel for HIV, hepatitis B, and syphilis screening in pregnant women was unveiled at the International AIDS Society (IAS) Conference on HIV Science in Kigali on July 15.

WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...